GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Welcome and introduction
Date
19 Sep 2021Session
GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumorsPresenters
Thierry AndréAuthors
T. AndréAuthor affiliations
- Medical Oncology Department, Hopital Saint-Antoine, 75571 - Paris/FR
Resources
Resources from the same session
Biomarkers for treatment with immune checkpoint inhibitors. Where are we now?
Presenter: Josef Rüschoff
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast
Efficacy and safety of immune checkpoint inhibitors in patients with dMMR/MSI-H advanced/recurrent endometrial cancer
Presenter: Anna Tinker
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast
Efficacy and safety of immune checkpoint inhibitors in patients with dMMR/MSI-H solid tumors
Presenter: Thierry André
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast
Patient case report panel discussion: Biomarkers in pan tumor treatment
Presenter: Anna Tinker
Session: GSK - Biomarkers for cancer immunotherapy: the importance of dMMR/MSI-H for predicting response in solid tumors
Resources:
Webcast